Trial Profile
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine (Primary) ; Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PRONTO-Peds
- Sponsors Eli Lilly and Company
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 07 Jun 2022 Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 24 Jan 2022 Primary endpoint has not been met according to the NCT results